{"doi":"10.1002/cti2.1195","title":"A novel autoantibody targeting calreticulin is associated with cancer in patients with idiopathic inflammatory myopathies","abstract":"OBJECTIVES: To investigate the prevalence and clinical significance of anti-calreticulin autoantibodies (anti-CRT Ab) in a large cohort of idiopathic inflammatory myopathy (IIM) patients. METHODS: Sera from 469 patients with IIM, 196 patients with other connective tissue diseases, 28 patients with solid tumors and 81 healthy controls were screened for anti-CRT Ab by enzyme-linked immunosorbent assay using human recombinant CRT protein. Sera from 35 IIM patients were tested using an immunoprecipitation assay to confirm the presence of anti-CRT Ab. Subsequently, IIM-cancer patients were identified and divided into new-onset, remission and recurrent groups based on their cancer status. The relationships between anti-CRT Ab levels and IIM disease activity were also investigated. RESULTS: Serum anti-CRT Ab was detected positive in 81 of the 469 (17.3%) IIM patients. Immunoprecipitated bands were observed at a molecular weight of 60 kDa corresponding to the CRT protein. The IIM patients with anti-CRT Ab more frequently had cancers compared to the patients without anti-CRT Ab. Moreover, the prevalence of anti-CRT Ab differed according to the cancer status. The IIM patients with recurrent cancers had a much higher prevalence of anti-CRT Ab than those with cancers in remission. Also, serum anti-CRT Ab levels positively correlated with disease activity at baseline and at follow-up visits. CONCLUSION: We report the existence of serum anti-CRT Ab in IIM patients and demonstrate the possible association of anti-CRT Ab with malignancy in IIM patients. Serum anti-CRT Ab could serve as a novel candidate marker of cancer in IIM patients.","journal":"Clinical & Translational Immunology","year":2020,"id":110657,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":6,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9623,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":269744,"name":"Heng Yang","orcid":"0000-0002-1491-4490","position":1,"is_corresponding":false},{"id":527540,"name":"Qiu‐Xiang Cheng","orcid":null,"position":2,"is_corresponding":false},{"id":526638,"name":"Yongpeng Ge","orcid":"0000-0003-3674-9307","position":3,"is_corresponding":false},{"id":526639,"name":"Qinglin Peng","orcid":"0000-0002-1271-1729","position":4,"is_corresponding":false},{"id":526640,"name":"Yamei Zhang","orcid":"0000-0003-4546-926X","position":5,"is_corresponding":false},{"id":104315,"name":"Genhong Cheng","orcid":"0000-0002-6713-2783","position":6,"is_corresponding":false},{"id":526641,"name":"Guochun Wang","orcid":"0000-0002-4616-9376","position":7,"is_corresponding":false},{"id":274882,"name":"Xin Lü","orcid":"0000-0002-0284-6478","position":8,"is_corresponding":false},{"id":292088,"name":"Honglei Chen","orcid":"0000-0003-3446-7779","position":0,"is_corresponding":true}],"reference_count":45,"raw_metadata":null,"created_at":"2026-07-18T23:13:01.914939Z","pmid":"33082955","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}